TRANSDERMALNOG FLASTERA на Английском - Английский перевод

• transdermal patch

Примеры использования Transdermalnog flastera на Хорватском языке и их переводы на Английский язык

Nakon uklanjanja transdermalnog flastera.
After removing the transdermal patch.

To je nova metoda za borbu protiv viška kilograma, na temelju transdermalnog flastera.
It is a new method of fighting excess pounds, based on a transdermal patch.

Osim toga, cijena transdermalnog flastera je samo 975 rubalja.
In addition, the price of the transdermal patch is only 975 rubles.

Potrebno je savjetovati bolesnike da pokriju mjesto primjene transdermalnog flastera, npr.
Patients must be advised to cover the transdermal patch application site, e.g.

Nakon uklanjanja transdermalnog flastera na koži može ostati ljepljivog materijala.
After removing the transdermal patch you may find some sticky material is left on your skin.

Operite ruke nakon primjene transdermalnog flastera.
Wash your hands after applying the transdermal patch.

Ljepljiva strana transdermalnog flastera pokrivena je čvrstom, dvodijelnom, plastičnom podlogom.
The sticky side of the transdermal patch is covered by a two-piece rigid plastic film.

Stanje dinamičke ravnoteže doseže se pri drugoj primjeni transdermalnog flastera.
Steady-state conditions are reached during the second application of the transdermal patch.

Potrebno je razmotriti korištenje transdermalnog flastera od 4, 6 mg/24 h kao početne i kao maksimalne doze u tih bolesnika.
Consider using the 4.6 mg/24 h transdermal patch both as initial and maximum dose in these patients.

Mjesto primjene držite pokrivenim još 10 dana nakon uklanjanja transdermalnog flastera.
Continue to keep the application site covered for a further 10 days after removing the transdermal patch.

Dan izmjene transdermalnog flastera isti je dan u svakom sljedećem tjednu 8., 15., 22. dan ciklusa te 1. dan sljedećeg ciklusa.
The transdermal patch Change Day will be on this day every week cycle Days 8, 15, 22 and Day 1 of the next cycle.

Nakon primjene rotigotin se kontinuirano otpušta iz transdermalnog flastera i apsorbira kroz kožu.
Following application, rotigotine is continuously released from the transdermal patch and absorbed through the skin.

Nakon skidanja transdermalnog flastera, srednje poluvrijeme eliminacije norelgestromina iznosi otprilike 28 sati, a etinilestradiola otprilike 17 sati.
Following removal of a transdermal patch, the mean elimination half-lives of norelgestromin and ethinyl estradiol were approximately 28 hours and 17 hours.

To nije utjecalo na poznati farmakokinetički profil transdermalnog flastera za vrijeme nošenja 7 dana.
The known pharmacokinetic profile of the transdermal patch over the period of wear(7 days) was not affected.

Nepromijenjeni rivastigmin nalazi se u tragovima u mokraći; glavni put eliminacije je izlučivanje metabolita putem bubrega nakon primjene transdermalnog flastera.
Unchanged rivastigmine is found in trace amounts in the urine; renal excretion of the metabolites is the major route of elimination after transdermal patch administration.

Ako nadlaktice nisu prikladne za primjenu transdermalnog flastera, liječnik Vam može predložiti da ga stavite na kožu trbuha.
If your arms are not suitable areas to apply the transdermal patch your doctor may ask you to put it on your abdomen.

Pazite da se transdermalni flaster ne zalijepi sam sa sobom i da ne dotičete ljepljivi dio transdermalnog flastera.
Be careful not to stick the transdermal patch to itself and avoid touching the sticky side of the transdermal patch.

Preostali hormonski djelatni sastojci transdermalnog flastera mogu imati štetan učinak ukoliko se nađu u vodenom okolišu.
Remaining hormonal active ingredients of the transdermal patch may have harmful effects if reaching the aquatic environment.

Bolesnici i njihovi njegovatelji moraju dobiti važne upute o primjeni Rivastigmin 3M Health Care Ltd. transdermalnog flastera vidjeti dio 4.2.
Patients and their caregivers must be instructed on important administration instructions for Rivastigmine 3M Health Care Ltd. transdermal patch see section 4.2.

U slučaju potpunog ili djelomičnog odljepljivanja transdermalnog flastera, potrebno ga je zalijepiti na isto mjesto uz pomoć medicinske ljepljive trake ako je potrebno.
In the event of a transdermal patch becoming completely or partially detached, the original transdermal patch should be reattached in the same position using medical tape if necessary.

Koncentracije norelgestromina odnosno etinilestradiola u stanju dinamičke ravnoteže u tjedan dana nošenja transdermalnog flastera su otprilike 0, 8 ng/ml odnosno 50 pg/ml.
Steady state concentrations of norelgestromin and EE during one week of transdermal patch wear are approximately 0.8 ng/ml and 50 pg/ml, respectively.

S obzirom na rezidualni sadržaj transdermalnog flastera nakon uklanjanja, apsorbira se otprilike 65% granizetrona, u prosječnoj dozi od 3, 1 mg dnevno.
Based on the measure of residual content of the transdermal patch after removal, approximately 65% of granisetron is delivered resulting in an average daily dose of 3.1 mg per day.

Kožu na kojoj je bio zalijepljen ovaj lijek držite pokrivenu još 10 dana nakon uklanjanja transdermalnog flastera kako biste je zaštitili od izravne sunčeve svjetlosti.
Keep the skin where this medicine was applied covered for another 10 days after the transdermal patch is taken off to protect from exposure to direct sunlight.

Rivastigmin se metabolizira brzo i u velikoj mjeri uz prividni poluživot eliminacije u plazmi od otprilike 3, 4 sata nakon uklanjanja transdermalnog flastera.
Rivastigmine is rapidly and extensively metabolised with an apparent elimination half-life in plasma of approximately 3.4 hours after removal of the transdermal patch.

Nakon primjene transdermalnog flastera, prividni poluvijek granizetrona u plazmi u zdravih ispitanika produžen je na približno 36 sati zbog spore apsorpcije granizetrona kroz kožu.
After transdermal patch application, the apparent granisetron plasma half-life in healthy subjects was prolonged to approximately 36 hours due to the slow absorption rate of granisetron through the skin.

Na zdravim ispitanicima ispitana je istovremena primjena jednog intravenskog bolusa od 0, 01 mg/kg granisetrona(najviše 1 mg) i transdermalnog flastera SANCUSO.
Concurrent administration of a single intravenous bolus of 0.01 mg/kg(maximum 1 mg) granisetron at the same time a SANCUSO transdermal patch was applied was investigated in healthy subjects.

Radi sprečavanja ometanja ljepljivih svojstava transdermalnog flastera, na površinu kože na koju će se primijeniti lijek ne smije se nanositi krema, losion ili puder.
To prevent interference with the adhesive properties of the transdermal patch, no cream, lotion or powder should be applied to the skin area where the medicinal product is to be applied.

Dok nosite transdermalni flaster, držite ga pokrivenim odjećom ako ćete se izlagati sunčevoj svjetlosti ili svjetlu UV-lampi, uključujući solarij, kožu na kojoj je bio zalijepljen SANCUSO držite pokrivenu još 10 dana nakon uklanjanja transdermalnog flastera kako biste je zaštitili od izravne sunčeve svjetlosti.
While you wear the transdermal patch, keep it covered with clothing if you will be in sunlight or near a sunlamp, including tanning beds keep the skin where SANCUSO was applied covered for another 10 days after the transdermal patch is taken off to protect from exposure to direct sunlight.

Potrebno je savjetovati bolesnike da pokriju mjesto primjene transdermalnog flastera, npr. odjećom, cijelo vrijeme tijekom nošenja flastera i još 10 dana nakon njegovog uklanjanja ako postoji opasnost od izlaganja sunčevoj svjetlosti.
Patients must be advised to cover the transdermal patch application site, e.g. with clothing, if there is a risk of exposure to sunlight throughout the period of wear and for 10 days following its removal.

Procjena prianjanja transdermalnog flastera u 621 bolesnika koji su primali transdermalne flastere s djelatnom tvari ili placebom, pokazala je da se pri primjeni u trajanju od 7 dana odlijepilo manje od 1% transdermalnih flastera..
An assessment of transdermal patch adhesion in 621 patients receiving either active or placebo transdermal patches showed that less than 1% of transdermal patches became detached over the course of the 7 day period of transdermal patch application.

Как использовать "transdermalnog flastera" в предложении

voziti ili upravljati strojevima za vrijeme primjene Bupain transdermalnog flastera ili tijekom 24 sata